<DOC>
	<DOCNO>NCT01493869</DOCNO>
	<brief_summary>The main objective study compare pharmacokinetics ( PK ) single oral 75 mg dose cabozantinib hepatic impaired adult subject healthy adult subject . Another objective ass safety tolerability cabozantinib adult subject .</brief_summary>
	<brief_title>Study Assess Pharmacokinetics Cabozantinib ( XL184 ) Hepatic Impaired Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Body weight must ≥50 kg &lt; 130 kg BMI ≥18 ( kg/m2 ) ≤36.0 ( kg/m2 ) . Must use acceptable form birth control course study 3 month follow single dose study drug . Female subject childbearing potential must negative pregnancy test screening checkin . Must adequate vital sign read screen checkin . Must able comply dietary fluid restriction require study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Normal healthy adult subject</keyword>
	<keyword>Adult subject hepatic impairment</keyword>
</DOC>